Dark Matter Blog

RNA State of Mind

Neil Kubica, PhD
October 25th, 2017
by Neil Kubica, PhD
Director of RNA Biology

Perspectives from the ‘Targeting RNA Using Small Molecules’ meeting @NYASciences #rSMs  Our team at Arrakis Therapeutics recently had the pleasure to co-sponsor the ‘Targeting RNA Using Small Molecules’ symposium at the New York Academy of Sciences. While several conference sessions over the years have focused on our favorite topic, including the (in)famous Gordon Conference that […]

Drugging the Undruggable: Transcription Factors

James Barsoum, PhD
July 12th, 2017
by James Barsoum, PhD
Senior Vice President of Biology, Arrakis

As we battle to expand the reach of modern therapeutics to treat diseases with high unmet need, we confront the limitations in our armamentarium. Most often we are limited by biology – we don’t understand the molecular drivers of disease and consequently don’t know which targets to aim at. But the more frustrating situation is […]

Discovering a New World of RNA-Targeted Medicines

Michael Gilman, PhD
February 27th, 2017
by Michael Gilman, PhD
CEO, Arrakis

So here we are. Nearly two years in the making, much of it focused, fastidious work by founder Russ Petter (of whom much more below), capped by an exhilarating and exhausting sprint to the finish by an outstanding team, Arrakis Therapeutics has now lifted off. Today we announced a $38M Series A financing led by […]

Escaping the Gravitational Pull of “Druggability”

Michael Gilman, PhD
February 22nd, 2017
by Michael Gilman, PhD
CEO, Arrakis

Most old-timers in drug discovery will agree on one thing: It never gets easier. Sure, maybe we learn a little from our mistakes along the way and the toolkit gets steadily flashier. But the easy targets, if ever they were truly easy ones, are long gone. We are left with either inscrutable biology or, even […]

Back to Top